Morgan Stanley analyst Toni Kaplan maintains Clarivate (NYSE:CLVT) with a Overweight and lowers the price target from $13 to $11.
Morgan Stanley Maintains Overweight on Clarivate, Lowers Price Target to $11
Morgan Stanley analyst Toni Kaplan maintains Clarivate (NYSE:CLVT) with a Overweight and lowers the price target from $13 to $11.
Related Posts
Here’s How Much You Would Have Made Owning Analog Devices Stock In The Last 15 Years
Analog Devices (NASDAQ:ADI) has outperformed the market over the past 15 years by 4.99% on an annualized basis…
Google Parent Alphabet Eyes HubSpot Acquisition: Bloomberg
Alphabet Inc (NASDAQ:GOOGL) eyes HubSpot Inc. (NYSE: HUBS) in a strategic move poised to reshape the CRM sector. With HubSpot's soaring market capitalization and Alphabet's vision to bolster its CRM foothold, the potential acquisition signals a significant shift in the tech landscape. Amidst the surge in HubSpot's shares, Alphabet's interest underscores its commitment to diversify and compete against CRM giants like Microsoft Corp (NASDAQ:MSFT) and Salesforce Inc (NYSE:CRM).
IFF Launches Axtra PHY GOLD Phytase Enzyme For In-Feed Use In The EU
International Flavors & Fragrances, Inc.'s (NYSE: IFF) unit Danisco Animal Nutrition & Health announced that its phytase enzyme,